Official websites use .gov
Secure .gov websites use HTTPS
« Previous
Next »
Titles
- A sense of déjà vu: the debate surrounding state biosimilar substitution laws1
- Alternative pricing models for remdesivir and other potential treatments for COVID-191
- Association of patient out-of-pocket costs with prescription abandonment and delay in fills of novel oral anticancer agents1
- CMS should bolster its oversight of manufacturer-submitted average sales price data to ensure accurate Part B drug payments1
- Calculation of potential inflation-indexed rebates for Medicare Part B drugs1
- Closing the "doughnut hole" has helped protect millions of Medicare beneficiaries from high drug costs1
- Competitive bidding in drug procurement: evidence from China1
- Drug discount program: federal oversight of compliance at 340B contract pharmacies needs improvement : report to Congressional requesters1
- Drug discount program: improvements needed in federal oversight of compliance at 340B contract pharmacies : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives1
- Drug discount program: status of agency efforts to improve 340B program oversight : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate1
- Drug industry: profits, research and development spending, and merger and acquisition deals : report to Congressional requesters1
- Drug price increases that exceed inflation are costing Medicare Part D billions1
- Drug price moderation in Germany: lessons for U.S. reform efforts1
- Equilibrium effects of pharmaceutical bundling: evidence from India1
- Estimated changes to employer-sponsored health insurance premiums due to the drug inflation rebate provision of the Build Back Better Act1
- Examining two approaches to U.S. drug pricing: international prices and therapeutic equivalency1
- Excluding noncovered versions when setting payment for two Part B drugs would have resulted in lower drug costs for Medicare and its beneficiaries1
- Fact sheet. The 340B Drug Pricing Program1
- Getting to lower prescription drug prices: the key drivers of costs and what policymakers can do to address them1
- Getting to the root of high prescription drug prices: drivers and potential solutions1